Cabergoline NDC 23155-823

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-823Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0823Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
23155-823-73	23155082373	8 TABLET in 1 BOTTLE (23155-823-73)Marketed from Jun 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cabergoline
Generic name (nonproprietary): cabergoline
Active ingredients: Cabergoline — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076310
Marketing start: Jun 15, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Ergolines (Chemical structure)
Identifiers: Product ID 23155-823_3bbcf6ce-236e-4298-81b3-f02cde1f98afSPL ID 3bbcf6ce-236e-4298-81b3-f02cde1f98afSPL set ID bc44d11b-b3f0-4e3d-9da3-4f8852d11734RxCUI 199703UNII LL60K9J05T
Pharmacologic class: Ergot Derivative

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N423155082373 followed by a unit qualifier and the quantity

Package 23155-0823-73. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 27, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Cabergoline Tablets, USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076310

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076310
Product	Strength	Form · route	Labeler	Product NDC
Cabergoline	Cabergoline .5 mg/1	TabletOral	SOLA Pharmaceuticals, LLC	70512-860
Cabergoline	Cabergoline .5 mg/1	TabletOral	A-S Medication Solutions	50090-6596